|Day's Range||43.50 - 43.75|
|52 Week Range||36.76 - 45.84|
|PE Ratio (TTM)||45.41|
|Dividend & Yield||1.06 (2.43%)|
|1y Target Est||N/A|
NEW DELHI/MUMBAI, April 28 (Reuters) - A group of global medical-technology companies plans to tell Indian officials next month that any further price control measures would risk future investments and make them less likely to introduce new products in the country, according to an industry source familiar with the matter. The lobbying effort by Abbott Laboratories, Boston Scientific, Johnson & Johnson and others comes after the government of Prime Minister Narendra Modi in February set a price cap for stents - small wire-mesh structures used to treat blocked arteries - slashing prices that patients pay for some devices by about 75 percent.
The market for implantable medical devices — pacemakers, defibrillators, hearing aids and other machines that help the body run — is expected to hit $26.75 billion by 2022, according to a new market research ...
Jim Cramer rattles off his take on caller favorite stocks, including this health care giant.